DermTech

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology.

[DermTech @DermTech]

Don’t miss Terry Arnold, PA-C, MBA, and Vice President of DermTech’s Medical Affairs team speak about living with intent and opportunities for Physician Assistants in industry.
Listen here: https://t.co/OG57LDehtv

[DermTech @DermTech]

DermTech is proud to support the Association of Military Dermatologists. If you missed us at the 2024 meeting, message us to learn more about TRICARE and VA coverage for the DermTech Melanoma Test.

[DermTech @DermTech]

New clinical study data presented at Winter Clinical: The Trust 2 Study included follow-up evaluations on 2-GEP performance from 5,096 lesions with biopsy results or confirmed clinical follow up.

https://t.co/JjC2sbb8p0

[DermTech @DermTech]

New in JDPA, "Genomics in Dermatology/Precision Medicine- More Than Sequence" by Love et al. highlights the role of genomics in dermatology, including the clinical utility of the DermTech Melanoma Test in guiding biopsy decisions. #Genomics
https://t.co/eOQwGefD81

[DermTech @DermTech]

New article from @DermTimesNow : Maral Kibarian Skelsey, MD, discusses the real-world implications of the new study's findings for dermatology clinicians.
Full interview here: https://t.co/dHRORj5o41

[DermTech @DermTech]

Check out our latest poster, “Non-invasive gene expression analysis rules out melanoma with high negative predictive value regardless of skin phototype” presented at the Winter Clinical Dermatology Conference (January 12-17, 2024).
https://t.co/cSQHUeETbo

[DermTech @DermTech]

“This is significant progress toward making this test available for patients with Fitzpatrick skin types IV-VI, which is important because ruling out melanoma in individuals with these skin types can be particularly challenging.”
https://t.co/Z53L4a7JIQ

[DermTech @DermTech]

"With an NPV that remains at 99% or higher, the DMT provides genomic information for a suspicious pigmented lesion that a clinician may be hesitant to biopsy for various reasons."
https://t.co/ENgWp7T9xu

[Dermatology Times @DermTimesNow]

A recent Winter Clinical Hawaii poster analyzed the ability of @DermTech's 2-GEP assay to detect the expression of LINC00518 and PRAME as a non-invasive assessment of clinically atypical, pigmented skin lesions to rule out #melanoma.

https://t.co/T02VJ1kNnO

[DermTech @DermTech]

“The Trust 2 Study illustrates that a high NPV test such as the DMT can allow physicians to confidently rule out melanoma for their patients,” commented Maral K. Skelsey, M.D., one of the lead Trust 2 Study investigators."
https://t.co/5ZuOYTeu4H

[DermTech @DermTech]

Headed to Winter Clinical 2024 in Hawaii? Send us a message to meet with our Medical Affairs team and learn more about the real-world utility of the DermTech Melanoma Test and our new Trust 2 Study data. We look forward to seeing you there! #WCH24

[DermTech @DermTech]

“The Trust 2 Study results reaffirm the DMT’s real-world clinical utility to rule out melanoma with a negative predictive value (NPV) that is higher than other currently available methods,” said Loren Clarke, M.D., chief medical officer, DermTech. 
https://t.co/MChqMfAgYY

[DermTech @DermTech]

Sending warm wishes for a festive holiday season to you and your loved ones! May this time be filled with joy, laughter, and cherished moments. #HappyHolidays

[DermTech @DermTech]

We are thrilled to announce that Mark Aguillard has joined our team as Chief Commercial Officer! Mark brings over 20 years of leadership experience driving growth through the development and commercialization of multiple, novel molecular diagnostics.

[Melanoma Research Foundation @CureMelanoma]

The MRF is proud to announce the 2023 San Diego Miles for Melanoma 5K Presented by @DermTech is now OPEN! Join us Sunday, October 15th at De Anza Cove Park. Click the link below to take advantage of our limited time early bird registration rates. https://t.co/Z9aeUQYvGW

[DermTech @DermTech]

We’re pleased to announce a favorable coverage policy for the Pigmented Lesion Assay (PLA), the foundational assay of the DMT, from Highmark Inc. Highmark and its Blue-branded affiliates provide health insurance to approx. 7M members in PA, WV, DE and NY. https://t.co/acL8hLqUdR

[DermTech @DermTech]

The innovative DermTech Gene Lab is:

☑️ CLIA certified
☑️ CAP accredited
☑️ Licensed by the New York State Department of Health

Learn more about integrating the DermTech Melanoma Test into your practice: https://t.co/IzY1l7H5MP.

#DermTech #Melanoma #PrecisionGenomics

[DermTech @DermTech]

Together, we can help end melanoma deaths by educating patients on the importance of skin exams and integrating the DermTech Melanoma Test into your practice. 🤝

Learn more by clicking the link below.

https://t.co/IzY1l7H5MP

#DermTech #melanoma #dermatology #skinchecks

[DermTech @DermTech]

The DermTech Melanoma Test detects key genomic markers associated with #melanoma to identify higher-risk lesions, potentially at their earliest stages.*

*Gerami P, et al. J Am Acad Dermatol. 2017;76(1):114-120.
Jackson S, et al. SKIN J Cutan Med. 2020;4(2):105-110.

[DermTech @DermTech]

Thank you @NewsChannel9 and @NeSommavilla for speaking with Dr. Ramsay Farah to discuss skin cancer awareness and showcase how the innovative DermTech Melanoma Test is revolutionizing melanoma assessment as we know it. https://t.co/EIdpMe1k3l.